Edmond De Rothschild (suisse) S.a. Lowers stake in Gilead Sciences (GILD)

Gilead Sciences (GILD) : Edmond De Rothschild (suisse) S.a. reduced its stake in Gilead Sciences by 13.61% during the most recent quarter end. The investment management company now holds a total of 87,545 shares of Gilead Sciences which is valued at $6,973,835 after selling 13,796 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.Gilead Sciences makes up approximately 2.24% of Edmond De Rothschild (suisse) S.a.’s portfolio.

Other Hedge Funds, Including , Oppenheimer Co Inc reduced its stake in GILD by selling 12,419 shares or 1.05% in the most recent quarter. The Hedge Fund company now holds 1,172,082 shares of GILD which is valued at $93,262,565. Gilead Sciences makes up approx 2.67% of Oppenheimer Co Inc’s portfolio.Cambridge Advisors reduced its stake in GILD by selling 270 shares or 3.0% in the most recent quarter. The Hedge Fund company now holds 8,739 shares of GILD which is valued at $714,763. Gilead Sciences makes up approx 0.32% of Cambridge Advisors’s portfolio.Balasa Dinverno Foltz boosted its stake in GILD in the latest quarter, The investment management firm added 1,255 additional shares and now holds a total of 11,207 shares of Gilead Sciences which is valued at $974,225. Gilead Sciences makes up approx 0.17% of Balasa Dinverno Foltz’s portfolio.Eqis Capital Management boosted its stake in GILD in the latest quarter, The investment management firm added 4,415 additional shares and now holds a total of 70,469 shares of Gilead Sciences which is valued at $6,125,870. Gilead Sciences makes up approx 0.40% of Eqis Capital Management’s portfolio.

Gilead Sciences opened for trading at $80.56 and hit $81.1757 on the upside on Friday, eventually ending the session at $81, with a gain of 0.51% or 0.41 points. The heightened volatility saw the trading volume jump to 82,27,939 shares. Company has a market cap of $106,892 M.

On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.

Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.

Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016.

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.